Henrik Schmidt

Consultant, Ass. Prof

Aarhus University Hospital

Denmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Henrik Schmidt is an Associate Professor at Aarhus University Hospital in Denmark. His research primarily focuses on the effects and outcomes of cancer treatments, particularly in metastatic melanoma and the implications of cardiotoxicity, acute kidney injury, and patient-reported outcomes. Recent publications highlight issues such as systemic therapy efficacy and the socioeconomic impacts on long-term cancer survivors.

Articles (9)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Henrik Birn

Professor

Aarhus Universitet Health

DENMARK

View details

Eva Ellebaek

Copenhagen University Hospital

DENMARK

View details

Christian Rønn Hansen

Odense University Hospital

DENMARK

View details

Christina H Ruhlmann

Associate Professor

University of Southern Denmark

DENMARK

View details

Niels Henrik I Hjollund

Aarhus University

DENMARK

View details

Inge Marie Svane

Københavns Universitet

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Henrik Schmidt

Research Interests

Contact this professor

About

Articles (9)

Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

Risk of and Mortality After Acute Kidney Injury Following Cancer Treatment: A Cohort Study

Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort

Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study

Health care and socioeconomic costs for long-term survivors after implementation of checkpoint-inhibitors and targeted agents for metastatic melanoma

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study

Effect of patient-reported outcomes as a dialogue-based tool in cancer consultations on patient self-management and health-related quality of life: a clinical, controlled trial

Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.

Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade

Collaborators (6)

Henrik Birn

Eva Ellebaek

Christian Rønn Hansen

Christina H Ruhlmann

Niels Henrik I Hjollund

Inge Marie Svane

Make your next move.